On November 25th 2016, the I Lab - Innovation & Leadership Advisory Board of Hikma Pharmaceuticals organized the second “iTech Event” at Hikma Manufacturing facility in Sintra, Portugal, targeting a global audience across this large industrial group, this time focusing on “Digital Healthcare”. Miguel Sales Dias, CEO of BIX CITIZEN, presented the topic “Telehealth - Monitoring Patient´s Vital Signs @ Home”, covering the recent trends and evolution of healthcare challenges at a global scale, particularly of the increase of chronic diseases such as diabetes or hypertension and discussing how personalized medicine along with home healthcare, including telemedicine and specially telehealth, are addressing these challenges and transforming healthcare today. The event followed with the presentation of Faris Hattar from Hikma, on “Serialization” specially applied to the problem of tracking and tracing globally pharmaceutical products, to protect patient safety and ensure product integrity fighting fraud, which will be a global requirement by 2018. Ana Isabel Lopes from Hikma, closed the event with a talk about “Serialization Beyond the Manufacturer”, addressing the challenges of tracking and tracing pharmaceutical drugs beyond the industry, up to the patient at home or at the Hospital, where 2D DataMatrix barcodes pay an important role
Hikma Pharmaceuticals is a global leader in developing, manufacturing and marketing a broad range of branded and non-branded generic pharmaceutical products, including injectables and oral solids, across the US, the MENA region and Europe. Hikma is also a leading licensing partner in the MENA region. With operations spanning over 50 countries, including 29 manufacturing plants and 6 R&D centers, Hikma had $1.4 billion of revenue in 2015 and shows a market capitalization of close to $6 billion.